Inventiva S.A.
Business
Inventiva S.A. is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH), a progressive chronic liver disease. The company's lead program is lanifibranor, a pan-PPAR agonist in Phase 3 development that has received FDA Breakthrough Therapy and Fast Track designations. Inventiva operates a wholly-owned research and development facility in France and has licensing partnerships with CTTQ for China and Hepalys for designated Asian territories to support lanifibranor's clinical development and potential commercialization.
Summary from 20-F filed 2026-04-08
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-354.10M |
| Total assets | $249.51M |
| Total liabilities | $278.03M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Inventiva S.A.'s CIK number?
Inventiva S.A.'s SEC CIK number is 0001756594 (1756594). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Inventiva S.A.'s SEC filings?
All of Inventiva S.A.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.